$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Nadofaragene Firadenovec对各亚组卡介苗无反应性NMIBC患者有持续疗效
2025-10-19 11:44:20
Check Details
新型抗病毒T细胞疗法有效治疗干细胞移植后的出血性膀胱炎
2025-10-19 11:44:20
Check Details
LiPax治疗非肌层浸润性膀胱癌具有较高的无复发缓解率
2025-10-19 11:44:20
Check Details
膀胱癌特效药厄达替尼每月费用多少钱
2025-10-19 11:44:20
Check Details
吡柔比星和吉西他滨哪个更好
2025-10-19 11:44:20
Check Details
针对膀胱癌的厄达替尼治疗效果怎么样
2025-10-19 11:44:20
Check Details
膀胱癌首款靶向药厄达替尼疗效如何?
2025-10-19 11:44:20
Check Details
首个针对膀胱癌的靶向药-厄达替尼
2025-10-19 11:44:20
Check Details
使用厄达替尼,生活中应该注意什么?
2025-10-19 11:44:20
Check Details
厄达替尼的疗效怎么样呢?厄达替尼的副作用有哪些?
2025-10-19 11:44:20
Check Details
FDA批准厄达替尼(Erdafitinib)靶向治疗转移性膀胱癌
2025-10-19 11:44:20
Check Details
首款治疗膀胱癌的靶向药厄达替尼获批上市!
2025-10-19 11:44:20
Check Details
1
2
...
212
213
214
215
216
217
218
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
2
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
3
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
4
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
5
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
6
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
7
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
8
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
9
Vemurafenib (Zelboraf) Complete Medication Guide
10
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
11
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
12
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options